opioid agonist-antagonist
This page covers all opioid agonist-antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting mu-opioid receptor.
Targets
Phase 3 pipeline (1)
- Oxycodone & naloxone combination, prolonged release · Mundipharma Research GmbH & Co KG · Pain management
Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist.
Patent intelligence
- opioid agonist antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates